Imprimis identifies formulations created for specific patient use, then performs a proprietary and rigorous evaluation process, known as Asset Review Methodology, or ARM™, to assess safety, efficacy and potential for commercialization.
Imprimis currently has several products under development:
- TriMox, a combination of triamcinolone acetonide and moxifloxacin hydrochloride, used as an injection during ocular surgery
- TriMox + Vancomycin, a combination of triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin, used as an injection during ocular surgery
- Lyophilized preservative-free and sulfite-free epinephrine, used as an injection during ocular surgery
- Shugarcaine, a lyophilized preservative-free and sulfite-free combination of epinephrine and lidocaine, used as an injection during ocular surgery
- A combination of tranexamic acid and bacitracin, for use in a topical cream for treatment of wound healing for patients in kidney dialysis centers
- Pentoxifylline, as an injection to treat Peyronie’s disease and other fibrotic conditions
- Impracor™, a treatment for renal-compromised patients of osteoarthritis, joint pain or inflammation
Imprimis has several paths for commercialization of these and other potential products:
- FDA approval, through the 505(b)(2) process. This process allows for a faster evaluation because our products are formulated with products already available on the market.
- Product out-licensing. Using our network of pharmacies, we can license our formulations to select pharmacies nationwide.
- Drug delivery technologies. We plan to out-license drug-delivery technologies to wholesalers to access the pharmacy market among others.